2-(1H-吡咯-2-基)-1,3-噻唑 | 295311-94-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 2-(1H-吡咯-2-基)-1,3-噻唑
• 中文别名: 2,3-哌嗪二酮,1,4-二羟基-5,5,6-三甲基-
• 英文名称: 2-thiazole-2-ylpyrrole
• 英文别名: 2-(1'H-pyrrol-2'-yl)thiazole；2-(1H-Pyrrol-2-yl)-1,3-thiazole；2-thiazol-2-ylpyrrole；2-(1H-pyrrol-2-yl)thiazole
• CAS: 295311-94-3
• 化学式: C₇H₆N₂S
• 分子量: 150.204
• InChiKey: PRALNEYHYQHWFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(1H-吡咯-2-基)-1,3-噻唑 在 吡啶 、 正丁基锂 、 四氯化钛 、 铜 、 锌 、 三氯氧磷 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 16.0h， 生成 3,20:10,13-diepithio-6,9:16,19-diimino-1,11-diaza[20]annulene
  参考文献：
  名称：

  21,23-Dithia-3,13-diazaporphycenes − Novel Aromatic Porphycene Analogues Incorporating Thiazole

  摘要：

  DOI：

  10.1002/1099-0690(200007)2000:13<2449::aid-ejoc2449>3.3.co;2-6
• 作为产物：
  描述：

  氯乙醛 、 1H-pyrrole-2-carbothioamide 在 乙酸酐 作用下， 以 甲苯 为溶剂， 反应 0.5h， 以80%的产率得到2-(1H-吡咯-2-基)-1,3-噻唑
  参考文献：
  名称：

  21,23-Dithia-3,13-diazaporphycenes − Novel Aromatic Porphycene Analogues Incorporating Thiazole

  摘要：

  DOI：

  10.1002/1099-0690(200007)2000:13<2449::aid-ejoc2449>3.3.co;2-6

文献信息

• Novel pyrrolyl-thiazole derivatives
  申请人：——

  公开号：US20040147572A1

  公开（公告）日：2004-07-29

  The present invention relates to compounds of formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

  本发明涉及公式(I)1中的化合物，其中R1、R2、R3、R4、R5、R6和R7如描述和索赔中定义，并其药用盐。这些化合物可用于治疗和/或预防与CB1受体调节相关的疾病。
• Microcin B17 Analogs And Methods For Their Preparation And Use
  申请人：Coquin Laurence

  公开号：US20080234132A1

  公开（公告）日：2008-09-25

  The present invention pertains to synthetic analogues of microcin B17 component units, methods of making and using these analogues, including, for example, as inhibitors of DNA gyrase. More particularly, the present invention pertains to compounds of the Formula wherein: W is independently: —H or a peptide group; Z is independently: —OH or a peptide group; wherein each peptide group, if present, is: an amino acid group and comprises exactly one amino acid, or: a poly(amino acid) group and comprises two or more amino acids; R N3 is independently: —H, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl, or C 3-6 cycloalkenyl, C 6-14 -carboaryl, C 5-14 heteroaryl, C 6-14 carboaryl-C 1-6 alkyl, C 5-14 heteroaryl-C 1-6 alkyl, and is optionally substituted; the circle represents a mono-heterocycle or a bis-heterocycle, wherein the heterocycle, or each of the two heterocycles, is a five membered ring having at least a first ring heteroatom that is N, and optionally a second ring heteroatom that is selected from N, O, and S; and the heterocycle, or each of the two heterocycles, is optionally substituted with one or more substituents; and pharmaceutically acceptable salts, amides, esters, solvates, and hydrates thereof. The present invention also pertains to uses of such compounds, for example, to inhibit DNA Gyrase activity in a cell and in methods of therapy, for example, to treat a disease or condition that is ameliorated by the inhibition of DNA Gyrase, such as a bacterial infection, cancer, etc.; as a herbicide; as a microbicide; as a bactericide; etc.

  本发明涉及微小肽B17组分单元的合成类似物，制备和使用这些类似物的方法，包括作为DNA酶抑制剂。更具体地说，本发明涉及以下式的化合物：其中：W独立地为：—H或肽基团；Z独立地为：—OH或肽基团；其中每个肽基团，如果存在，则为：氨基酸基团，包括恰好一个氨基酸，或：多肽（氨基酸）基团，包括两个或更多氨基酸；RN3独立地为：—H、C1-6烷基、C2-6烯基、C3-6环烷基或C3-6环烯基、C6-14芳基、C5-14杂芳基、C6-14芳基-C1-6烷基、C5-14杂芳基-C1-6烷基，并且可选地被取代；圆圈表示单杂环或双杂环，其中杂环或两个杂环中的每一个都是具有至少一个第一环杂原子的五元环，该原子是N，可选地，第二环杂原子是从N、O和S中选择的；并且该杂环或两个杂环可选地被一个或多个取代基取代；以及其药学上可接受的盐、酰胺、酯、溶剂化物和水合物。本发明还涉及这些化合物的用途，例如，在细胞中抑制DNA酶活性和治疗方法中使用，例如治疗通过抑制DNA酶改善的疾病或病况，如细菌感染、癌症等；作为除草剂；作为杀菌剂；作为杀菌剂等。
• Phenylpyrrole derivative
  申请人：Daiichi Sankyo Company, Limited

  公开号：US08017610B2

  公开（公告）日：2011-09-13

  The present invention relates to a compound or a pharmacologically acceptable salt thereof having superior glucokinase activating activity, and is a compound represented by general formula (I), or pharmacologically acceptable salt thereof: [wherein, A represents, for example, an oxygen atom or sulfur atom, R1 represents, for example, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 halogenated alkyl group, A and R1 together with the carbon atom bonded thereto form a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R2 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group α or a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R3 represents a hydroxy group or a C1-C6 alkoxy group, and Substituent Group α consists of, for example, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkyl group substituted with 1 or 2 hydroxy group(s), a C1-C6 alkylsulfonyl group, and a group represented by the formula —V—NR5R6 (wherein, V represents a carbonyl group or a sulfonyl group, and R5 and R6 may be the same or different and respectively represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 together with the nitrogen atom bonded thereto form a 4- to 6-membered saturated heterocycle that may be substituted with 1 or 2 group(s) independently selected from a C1-C6 alkyl group and a hydroxy group, and the 4- to 6-membered saturated heterocycle may further contain one oxygen atom or nitrogen atom)].

  本发明涉及一种具有优越的葡萄糖激酶激活活性的化合物或其药理学上可接受的盐，该化合物由通式（I）表示，或其药理学上可接受的盐：[其中，A代表例如氧原子或硫原子，R1代表例如C1-C6烷基、C1-C6烷氧基或C1-C6卤代烷基，A和R1与其结合的碳原子形成可能被1到3个独立选择的取代基α取代的杂环基，R2代表可能被1到5个独立选择的取代基α取代的苯基或可能被1到3个独立选择的取代基α取代的杂环基，R3代表羟基或C1-C6烷氧基，取代基α由例如卤素原子、C1-C6烷基、带有1或2个羟基的C1-C6烷基、C1-C6烷基磺酰基和由公式—V—NR5R6表示的基组成（其中，V代表羰基或磺酰基，R5和R6可能相同或不同，分别代表氢原子或C1-C6烷基，或者R5和R6与其结合的氮原子形成可能被1或2个独立选择的C1-C6烷基和羟基取代的4-6环饱和杂环，4-6环饱和杂环还可能含有一个氧原子或氮原子）。
• Construction of bi(hetero)aryls <i>via</i> dicyanopyrazine-mediated photochemical cross-coupling
  作者：Zuzana Burešová、Veronika Jandová、Milan Klikar、Monika Grygarová、Filip Bureš

  DOI：10.1039/d2ob01836e

  日期：——

  photochemical cross-coupling protocol towards bi(hetero)aryls has been developed. The coupling reactions were mediated by dicyanopyrazine photoredox catalyst, while a photoinduced disproportionation process has been identified as an accompanying mechanism, especially for pyrrole derivatives. The developed method allows the cross-coupling of five-membered rings such as pyrrole, imidazole, thiazole and

  已经开发了针对双（杂）芳基的光化学交叉偶联方案。偶联反应由二氰基吡嗪光氧化还原催化剂介导，而光诱导歧化过程已被确定为伴随机制，特别是对于吡咯衍生物。开发的方法允许交叉偶联五元环，如吡咯、咪唑、噻唑和恶唑以及各种二嗪（吡啶和嘧啶）和苯衍生物。还公开了一种似是而非的反应机制。通过构建阿托伐他汀核心或通过苯并[ c的逐渐功能化，证明了所开发方法的实际应用和相关性][1,2,5]噻二唑。总共制备了 21 个双（杂）芳基化合物，产率在 19% 到 95% 之间。
• LIQUID CRYSTAL COMPOSITION
  申请人：Sumitomo Chemical Company, Limited

  公开号：US20170335191A1

  公开（公告）日：2017-11-23

  A liquid crystal composition which prevents production of an alignment defect of a liquid crystal compound and also has excellent storage stability during dissolution in a solvent is provided. The liquid crystal composition is suitable for constituting a retardation film capable of favorable circular polarization conversion. The liquid crystal composition includes a polymerizable liquid crystal compound having 3 or more ring structures in the main chain, and aluminum. A content of the aluminum is 1 ppm or more and 170 ppm or less relative to the polymerizable liquid crystal compound.

  提供了一种液晶组合物，可以防止液晶化合物的对准缺陷产生，并且在溶剂中溶解时具有优异的储存稳定性。该液晶组合物适用于构成具有良好圆偏振转换的减速膜。该液晶组合物包括具有3个或更多环结构的可聚合液晶化合物和铝。铝的含量相对于可聚合液晶化合物为1 ppm或更多，170 ppm或更少。